Tang Qisheng, Lian Yuxi, Yu Jinhua, Wang Yuanyuan, Shi Zhifeng, Chen Liang
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Department of Electronic Engineering, Fudan University, Shanghai, China.
BMC Neurol. 2017 Sep 15;17(1):183. doi: 10.1186/s12883-017-0961-8.
Tumor location served as an important prognostic factor in glioma patients was considered to postulate molecular features according to cell origin theory. However, anatomic distribution of unique molecular subtypes was not widely investigated. The relationship between molecular phenotype and histological subgroup were also vague based on tumor location. Our group focuses on the study of glioma anatomic location of distinctive molecular subgroups and histology subtypes, and explores the possibility of their consistency based on clinical background.
We retrospectively reviewed 143 cases with both molecular information (IDH1/TERT/1p19q) and MRI images diagnosed as cerebral diffuse gliomas. The anatomic distribution was analyzed between distinctive molecular subgroups and its relationship with histological subtypes. The influence of tumor location, molecular stratification and histology diagnosis on survival outcome was investigated as well.
Anatomic locations of cerebral diffuse glioma indicate varied clinical outcome. Based on that, it can be stratified into five principal molecular subgroups according to IDH1/TERT/1p19q status. Triple-positive (IDH1 and TERT mutation with 1p19q codeletion) glioma tended to be oligodendroglioma present with much better clinical outcome compared to TERT mutation only group who is glioblastoma inclined (median overall survival 39 months VS 18 months). Five molecular subgroups were demonstrated with distinctive locational distribution. This kind of anatomic feature is consistent with its corresponding histological subtypes.
Each molecular subgroup in glioma has unique anatomic location which indicates distinctive clinical outcome. Molecular diagnosis can be served as perfect complementary tool for the precise diagnosis. Integration of histomolecular diagnosis will be much more helpful in routine clinical practice in the future.
肿瘤位置被认为是胶质瘤患者的一个重要预后因素,根据细胞起源理论推测其具有分子特征。然而,独特分子亚型的解剖分布尚未得到广泛研究。基于肿瘤位置,分子表型与组织学亚组之间的关系也不明确。我们团队专注于研究胶质瘤独特分子亚组和组织学亚型的解剖位置,并基于临床背景探索它们一致性的可能性。
我们回顾性分析了143例同时具有分子信息(IDH1/TERT/1p19q)和MRI图像且被诊断为脑弥漫性胶质瘤的病例。分析了不同分子亚组之间的解剖分布及其与组织学亚型的关系。还研究了肿瘤位置、分子分层和组织学诊断对生存结果的影响。
脑弥漫性胶质瘤的解剖位置表明临床结果各异。基于此,根据IDH1/TERT/1p19q状态可将其分为五个主要分子亚组。三阳性(IDH1和TERT突变伴1p19q共缺失)胶质瘤倾向于少突胶质细胞瘤,与仅TERT突变组(倾向于胶质母细胞瘤)相比,临床结果要好得多(中位总生存期39个月对18个月)。五个分子亚组具有独特的位置分布。这种解剖特征与其相应的组织学亚型一致。
胶质瘤中的每个分子亚组都有独特的解剖位置,这表明了不同的临床结果。分子诊断可作为精确诊断的完美补充工具。组织分子诊断的整合在未来的常规临床实践中将更有帮助。